Advertisement

Lymphoma

  • Sigrid Cherrier-De Wilde
Chapter

Abstract

Lymphomas are subdivided in Hodgkin’s disease (HD) and non-Hodgkin’s lymphomas (NHL). Essentially the medications used are of two types: monoclonal antibodies and chemotherapy. The side effects of treatment are grouped accordingly. The most commonly used treatment protocol in NHL is a combination of a monoclonal antibody with polychemotherapy. Hence, this chapter is subdivided according to these two treatment modalities.

Keywords

Hodgkin’s disease Non-Hodgkin’s lymphomas Chemotherapy Monoclonal antibodies 

References

  1. 1.
    Smith MR. Antibodies and hematologic malignancies. Cancer J. 2008;14(3):184–90.CrossRefPubMedGoogle Scholar
  2. 2.
    Armitage JO. How I treat patients with diffuse large B-cell lymphoma. Blood. 2007;110(1):29–36.CrossRefPubMedGoogle Scholar
  3. 3.
    Cheson BD, Leonard JP. Monoclonal antibody therapy for B-cell non-Hodgkin’s lymphoma. N Engl J Med. 2008;359:613–26.CrossRefPubMedGoogle Scholar
  4. 4.
    Friedberg JW, Vose JM, Kelly JL, Young F, Bernstein SH, Peterson D, et al. The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma. Blood. 2011;117:2807–12.  https://doi.org/10.1182/blood-2010-11-314708.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Rummel MJ, Niederle N, Maschmeyer G, Banat AG, von Gruenhagen U, Losem C, et al. Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent and mantle cell lymphomas (MCL): updated results from the StiL NHL1 study. J Clin Oncol. 2012;30:3.CrossRefGoogle Scholar
  6. 6.
    Goede V, Fischer K, Humphrey K, Asikanius E, et al. Obinutuzumab (GA101) + chlorambucil or rituximab + Clb versus Clb alone in patients with CLL and co-existing medical conditions: final stage I results of the CLL11 phase 3 trial. N Engl J Med. 2014;370:1101–10.CrossRefPubMedGoogle Scholar
  7. 7.
    Wierda WG, Kipps TJ, Dürig J, et al. Chemoimmunotherapy with OFC in previously untreated patients with chronic lymphocytic leukemia. Blood. 2011;117(24):6450–8.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J Clin Oncol. 2012;30(18):2183–9.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Larocca A, Cavallo F, Bringhen S, et al. Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. Blood. 2012;119(4):939–9.CrossRefPubMedGoogle Scholar
  10. 10.
    Oehrlein K, Langer C, Sturm I, et al. Successful treatment of patients with multiple myeloma and impaired renal function with lenalidomide: results of 4 German centers. Clin Lymphoma Myelome Leuk. 2012;12(3):191–6.CrossRefGoogle Scholar
  11. 11.
    Savage KJ, Skinnider B, Al-Mansour M, Sehn LH, Gascoyne RD, Connors JM. Treating limited-stage nodular lymphocyte predominant Hodgkin lymphoma similarly to classical Hodgkin lymphoma with ABVD may improve outcome. Blood. 2011;118:4585–90.  https://doi.org/10.1182/blood-2011-07-365932.CrossRefPubMedGoogle Scholar
  12. 12.
    Zinzani PL. Clinical experience with fludarabine in indolent non-Hodgkin’s lymphoma. Hematol J. 2004;5(Suppl 1):S38–49.CrossRefPubMedGoogle Scholar
  13. 13.
    Economopoulos T, Psyrri A, Fountzilas G, Tsatalas C, Anagnostopoulos A, Papageorgiou S, et al. Phase II study of low-grade non-Hodgkin lymphomas with fludarabine and mitoxantrone followed by rituximab consolidation: promising results in marginal zone lymphoma. Leuk Lymphoma. 2008;49(1):68–74.CrossRefPubMedGoogle Scholar
  14. 14.
    Johnson SA. Use of fludarabine in the treatment of mantle cell lymphoma, Waldenström’s macroglobulinemia and other uncommon B- and T-cell lymphoid malignancies. Hematol J. 2004;5(Suppl 1):S50–61.CrossRefPubMedGoogle Scholar
  15. 15.
    Weidmann E, Kim SZ, Rost A, Schuppert H, Seipelt G, Hoelzer D, Mitrou PS. Bendamustine is effective in relapsed or refractory aggressive non-Hodgkin’s lymphoma. Ann Oncol. 2012;13(8):1285–9.CrossRefGoogle Scholar
  16. 16.
    Ohmachi K, Ando K, Ogura M, Uchida T, Itoh K, Kubota N, Japanese Bendamustine Lymphoma Study Group, et al. Multicenter phase II study of bendamustine for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma. Cancer Sci. 2010;101(9):2059–64.CrossRefPubMedGoogle Scholar
  17. 17.
    Moreau P, Pylypenko H, Grosicki S, et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol. 2011;12(5):431–40.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of HematologyCentre Hospitalier de LuxembourgLuxembourgLuxembourg

Personalised recommendations